Search results for "Quinolone"

showing 8 items of 108 documents

Microwave-Assisted Synthesis of Polysubstituted 4-Quinolones from Deprotonated α-Aminonitriles

2010

The α-alkylation of deprotonated N-aryl-α-aminonitriles with α-bromoesters furnishes intermediates that can be cyclized to 4-quinolones upon microwave irradiation. Alternatively, base-induced dehydrocyanation of the alkylation products furnishes enaminoesters, which can, for example, be converted into quinoline-3-carboxylates.

chemistry.chemical_compoundDeprotonationMicrowave chemistryChemistryOrganic Chemistry4-quinolonesMicrowave irradiationCarboxylatePhysical and Theoretical ChemistryAlkylationPhotochemistryChemical synthesisMicrowaveEuropean Journal of Organic Chemistry
researchProduct

Current development of CFTR potentiators in the last decade

2020

Cystic fibrosis (CF) is a genetic disorder produced by the loss of function of CFTR, a main chloride channel involved in transepithelial salt and water transport. CFTR function can be rescued by small molecules called "potentiators" which increase gating activity of CFTR on epithelial surfaces. High throughput screening (HTS) assays allowed the identification of new chemical entities endowed with potentiator properties, further improved through medicinal chemistry optimization. In this review, the most relevant classes of CFTR potentiators developed in the last decade were explored, focusing on structure-activity relationships (SAR) of the different chemical entities, as a useful tool for t…

congenital hereditary and neonatal diseases and abnormalitiesHigh-throughput screeningGlycineComputational biologyQuinolonesVX-770Aminophenols01 natural sciencesCystic fibrosisCystic fibrosisSmall Molecule LibrariesStructure-Activity Relationship03 medical and health sciencesDrug DiscoverymedicineHumansCFTR potentiatorCFTRLoss function030304 developmental biologyPharmacology0303 health sciencesWater transportbiology010405 organic chemistryChemistryOrganic ChemistryCFTR potentiatorsBiological activityGeneral MedicineTriazolesPotentiatormedicine.diseaseCystic fibrosis transmembrane conductance regulator0104 chemical sciencesCystic fibrosiMutationChloride channelbiology.proteinCystic fibrosis transmembrane conductance regulatorEuropean Journal of Medicinal Chemistry
researchProduct

Recent development in fluorinated antibiotics

2019

This chapter presents the most recent results in the development of fluorinated antibioticsby taking into consideration modern challenges of multidrug-resistant pathogens. After a brief introduction on the direct and indirect effects of fluorine and fluorinated moieties in regulating biological activity, the chapter is developed in three main subsections discussing the two major classes of fluorinated antibiotics, fluoroquinolones and oxazolidinones, plus an overview of recent research on the antibiotic activity of fluorinated analogs of tetracyclines, peptidomimetics, triazoles, and nucleosides. Discussed aspects include: (1) Synthesis and challenges posed by the introduction of fluorinate…

medicine.drug_classChemistryPeptidomimeticAntibiotics Fluorinated heterocycles Multidrug resistance Oxazolidinones QuinolonesAntibioticsmedicineSettore CHIM/06 - Chimica OrganicaCombinatorial chemistry
researchProduct

Multiple Resistance to Betalactam Antibiotics, Azithromycin or Moxifloxacin in Implant Associated Bacteria

2013

Background Antibiotics are more and more frequently prescribed in dentistry for prevention and treatment of oral diseases. Bacterial resistance to these agents is clearly increasing, including even previously susceptible micro-organisms and true pathogens. The aim of the present investigation was to examine resistant bacterial strains with respect to possible multiple antibiotic resistance. Methods In a previous investigation, implant-associated bacteria were tested first as mixed cultures and again as pure isolates (n = 138) for resistance to one of five antibiotics (ampicillin/AM, ampicillin + sulbactam/AB, azithromycin/AZ, penicillin/PG, moxifloxacin/MX) using the Etest. The resistance o…

medicine.drug_classMoxifloxacinAntibioticsMicrobial Sensitivity TestsDrug resistanceAzithromycinbeta-LactamsGeneral Biochemistry Genetics and Molecular BiologyMicrobiologyAntibiotic resistanceMoxifloxacinAmpicillinmedicineHumansEtestDental ImplantsAza CompoundsBacteriabusiness.industryDrug Resistance MicrobialSulbactamDrug Resistance MultiplePenicillinQuinolinesbusinessFluoroquinolonesmedicine.drugClinical Laboratory
researchProduct

Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.

2000

ABSTRACT We conducted a quantitative structure-activity relationship study using a database of 158 quinolones previously tested against Mycobacterium avium-M. intracellulare complex in order to develop a model capable of predicting the activity of new quinolones against the M. avium-M. intracellulare complex in vitro. Topological indices were used as structural descriptors and were related to anti- M. avium-M. intracellulare complex activity by using the linear discriminant analysis (LDA) statistical technique. The discriminant equation thus obtained correctly classified 137 of the 158 quinolones, including 37 of a test group of 44 randomly chosen compounds. This model was then applied to 2…

medicine.drug_classStereochemistryComputational biologyModels BiologicalStructure-Activity RelationshipAnti-Infective AgentsMoxifloxacinPredictive Value of TestsmedicinePharmacology (medical)Computer SimulationMechanisms of Action: Physiological EffectsAntibacterial agentPharmacology4-QuinolonesbiologyLinear discriminant analysisbiology.organism_classificationQuinoloneMycobacterium avium ComplexGatifloxacinInfectious DiseasesSparfloxacinMolecular topologymedicine.drugMycobacteriumAntimicrobial agents and chemotherapy
researchProduct

Anti- Toxoplasma Activities of 24 Quinolones and Fluoroquinolones In Vitro: Prediction of Activity by Molecular Topology and Virtual Computational Te…

2000

ABSTRACT The apicoplast, a plastid-like organelle of Toxoplasma gondii , is thought to be a unique drug target for quinolones. In this study, we assessed the in vitro activity of quinolones against T. gondii and developed new quantitative structure-activity relationship models able to predict this activity. The anti- Toxoplasma activities of 24 quinolones were examined by means of linear discriminant analysis (LDA) using topological indices as structural descriptors. In parallel, in vitro 50% inhibitory concentrations (IC 50 s) were determined in tissue culture. A multilinear regression (MLR) analysis was then performed to establish a model capable of classifying quinolones by in vitro acti…

medicine.drug_classStereochemistryMolecular ConformationBiologyModels BiologicalStructure-Activity RelationshipAnti-Infective AgentsPredictive Value of TestsMoxifloxacinparasitic diseasesmedicineAnimalsStructure–activity relationshipComputer SimulationPharmacology (medical)Mechanisms of Action: Physiological EffectsAntibacterial agentPharmacology4-QuinolonesBiological activityQuinoloneGatifloxacinGrepafloxacinTrovafloxacinInfectious DiseasesRegression AnalysisToxoplasmaFluoroquinolonesmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Mechanism of New Antipsychotic Medications

2003

Antagonism of D 2 -like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80%(striatal) D 2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D 2 -like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is ari…

medicine.medical_specialtyPsychosismedicine.drug_classmedicine.medical_treatmentAripiprazoleAtypical antipsychoticQuinolonesPharmacologyPartial agonistPiperazinesBasal Ganglia DiseasesArts and Humanities (miscellaneous)Dopamine receptor D2Internal medicinemedicineHumansAntipsychoticDose-Response Relationship DrugReceptors Dopamine D2Putamenmedicine.diseaseCorpus StriatumProlactinDopamine D2 Receptor AntagonistsPsychiatry and Mental healthEndocrinologyMechanism of actionDopamine receptorSchizophreniaAripiprazolemedicine.symptomPsychologyAntipsychotic AgentsTomography Emission-Computedmedicine.drugArchives of General Psychiatry
researchProduct

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…

2014

Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…

β2-agonistPulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationKaplan-Meier EstimateQuinolonesPlaceboDrug Administration SchedulePooled analysisExacerbationsPulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodForced Expiratory VolumeInternal medicineHumansCOPDMedicineAdrenergic beta-2 Receptor AgonistsRandomized Controlled Trials as TopicIndacaterolCOPDDose-Response Relationship Drugbusiness.industryMinimal clinically important differenceHazard ratiomedicine.diseaseConfidence intervalBronchodilator AgentsClinical Trials Phase III as TopicAnesthesiaIndansIndacaterolbusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct